Biovica International has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several expected work orders, the first of which is SEK 1.7 million. This service agreement enables the evaluation of cell proliferation activities in pivotal drug development studies.

The test service is focused on the use of the Biovica's TKa assay and expertise within the interpretation of TKa measurement dynamics.